Table 2.

Clinical characteristics of patients with NMOSD and MS in relapse phase

	NMOSD (n = 26)	MS (n = 18)
Disease duration, months (range)	42.7 (0–240)	62.4 (0–204)
Period from the acute relapse to CSF sampling, days (range)	14 (1–30)	19.2 (1–60)
Location of lesion
Spinal cord (%)	23 (88.4)	5 (27.7)
Brain (%)	2 (7.6)	14 (77.7)
Optic nerve (%)	2 (7.6)	2 (11.1)
Length of spinal cord involvement, number of segments (range)	5.8 (2–17)	1.4 (1–2)
Treatment at CSF sampling (%)	7 (26.9)	11 (61.1)
Prednisolone	6 (23.0)	–
Immunosuppressants	4 (15.3)	–
Interferon-β	–	7 (38.8)
Fingolimod	–	3 (16.6)
Dimethyl fumarate	–	1 (5.5)

NMOSD neuromyelitis optica spectrum disorder, MS multiple sclerosis, CSF cerebrospinal fluid